Effects of Imfluna, an Iranian traditional polyherbal medicine, on COVID-19 symptoms: A randomized, double-blind and placebo-controlled clinical trial

The current pandemic of Coronavirus disease 2019 (COVID-19) and severity of the infection and high mortality have almost unprecedented challenges in the health systems of most countries around the world.

The present study aimed to evaluate the effect of Iranian traditional polyherbal medicine (Imfluna) containing a mixture of echinacea, stachys, artemisia, hyssopus, polybody, alpinia, ginger, and ginseng extract on symptoms of COVID-19 infected patients.

In this placebocontrolled and double-blind clinical trial, a total of 60 voluntarily approved patients with COVID-19 were randomly assigned to the placebo and Imfluna groups. Patients in each group, in addition to receiving standard medications, took two 500 mg capsules of Imflona or placebo every 8 hours for 2 weeks. The patient's vital signs, including the severity of shortness of breath, cough, and body temperature, were recorded during the study. Also blood ESR, liver and kidney function tests were performed at baseline and endpoint.

The results showed that patients in the Imfluna-treated group had significantly greater improvement in daily cough, shortness of breath and ESR compared with the placebo group. In addition, lung lesions improved in the Imfluna-treated group, although not significantly.

Patients with COVID-19 who were treated with Imfluna for 2 weeks had better comfort and fewer symptoms associated with the disease with no any drug side effects.